Brief: Armata Pharmaceuticals Announces Completion Of Its Phase 1B/2A 'Swarm-P.A.' Study Of Inhaled AP-Pa02 In Cystic Fibrosis Subjects With Chronic Pulmonary Pseudomonas Aeruginosa Infection
22/12/2022 13:16
Dec 22 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES COMPLETION OF ITS PHASE
1B/2A
'SWARM-P.A.' STUDY OF INHALED AP-PA02 IN CYSTIC FIBROSIS
SUBJECTS WITH CHRONIC PULMONARY PSEUDOMONAS AERUGINOSA INFECTION
Source text for Eikon: ID:nPn7fgrtxa
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles